The Role of Complement Component C3b and Its Receptors in Sperm-Oocyte Interaction (Ferilzation/Inferility) DEBORAH J

Total Page:16

File Type:pdf, Size:1020Kb

The Role of Complement Component C3b and Its Receptors in Sperm-Oocyte Interaction (Ferilzation/Inferility) DEBORAH J Proc. Natl. Acad. Sci. USA Vol. 90, pp. 10051-10055, November 1993 Developmental Biology The role of complement component C3b and its receptors in sperm-oocyte interaction (ferilzation/inferIlity) DEBORAH J. ANDERSON*t, AMY F. ABBOTT*, AND RICHARD M. JACKt *Fearing Research Laboratory, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, and tDepartment of Rheumatology and Immunology, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston, MA 02115 Communicated by K. Frank Austen, June 30, 1993 ABSTRACT Previous studies have shown that human functions other than binding and regulation of complement sperm that have undergone the acrosome reaction express a component C3b. Monoclonal antibodies (mAbs) directed unique tissue-specific variant of the complement component 3 against MCP inhibit the penetration of hamster oocytes by (C3)-binding molecule membrane cofactor protein (MCP, human sperm (2-4), suggesting that MCP and perhaps C3 also CD46) and that damaged or dead sperm activate the alternative play a role in sperm-oocyte interaction. To further define the pathway of complement and bind C3 catabolites. In this study role of C3 and its binding proteins in sperm-ovum interac- we provide evidence that MCP on sperm that have undergone tions, we assessed the expression of other C3-binding pro- the acrosome reaction specifically binds dimeric C3b and that teins and receptors on sperm and oocytes, the effects of human sperm acrosomal proteases released during the ac- sperm acrosomal enzymes on C3 cleavage to C3b, and the rosome reaction directly cleave C3, facilitating its binding to binding of C3 and C3b to gametes. We also investigated the MCP. Furthermore, human and hamster oocytes can activate effects of C3b and antibodies to C3 on sperm penetration of the alternative pathway of complement and also bind human oocytes. The data support a role for complement-binding C3 fragments. Monoclonal antibodies specific for complement proteins and C3 fragments in human gamete interactions receptors type 1 (CD35) and type 3 (CD11b/CD18) bind to the leading to fertilization. human oocyte plasma membrane, indicating that specific com- plement-binding molecules may play a role in the attachment of C3 catabolites to oocytes. Subsaturating concentrations of MATERIALS AND METHODS dimeric C3b (0.01-1 FM) promoted penetration of hamster Gamete Preparation. Semen donors were healthy men oocytes by human sperm, whereas saturating doses (>10 FM) between 22 and 38 yr old with normal semen parameters. inhibited this process. In addition, antibodies to both MCP and Motile sperm were isolated from fresh liquified semen by C3 signiicantly inhibited penetration of hamster oocytes by swim-up technique or centrifugation through discontinuous human sperm. These data provide evidence that regulated 47%/90%o Percoll (Pharmacia) gradients (7). AR sperm were gamete-induced generation of C3 fragments and the binding of prepared by incubation with 5 ,uM calcium ionophore A23187 these fragments by selectively expressed receptors on sperm in Ham's F-10 medium (GIBCO)/3.5% human serum albumin and oocytes may be an initial step in gamete interaction, leading (HSA; Sigma) at 37°C for 30 min (2). Human ova were to membrane fusion and fertilization. obtained from the Brigham and Women's Hospital In Vitro Fertilization Service (courtesy ofR. Clarke and K. Jackson). Mammalian fertilization entails a complex series of events Methods for ovulation induction and oocyte retrieval have including (i) attachment of sperm to the zona pellucida of the been described (8). Hamster oocytes were obtained from oocyte via receptors on the sperm plasma membrane; (ii) the sexually mature female golden hamsters, Mesocricetus au- sperm acrosome reaction (AR), exocytosis of the acrosomal ratus (Charles River Breeding Laboratories) (9). Oocytes contents from the acrosome, a specialized granule containing were washed and resuspended in sperm washing medium proteases and other degradative enzymes; (iii) penetration of (SWM; Irvine Scientific), which contains HSA at 5 mg/ml sperm through the zona pellucida, which occurs concurrently and was supplemented with 10% heat-inactivated fetal calf with the AR; (iv) attachment of sperm to the oocyte plasma serum (GIBCO). For some experiments, oocytes were trans- membrane (oolema) via receptors exposed on the sperm ferred to a drop ofTyrode's salt solution (Sigma), pH 2.0, to surface after the AR; and (v) sperm-oocyte fusion. Receptors dissolve the zona pellucida (10). and ligands mediating these events are only now beginning to Immunofluorescence Staining and Microscopy. Expression be identified and characterized (1). of complement-binding proteins and receptors on gamete Recently, we and others have shown that human sperm membranes was assessed by indirect fluorescence staining. that have undergone the AR express membrane cofactor Sperm (1 x 106 in 0.1 ml of Ham's F-10 medium/0.3% HSA) protein (MCP, CD46), a complement component 3 (C3)- or ova (2 ova per 0.1 ml of F-10/HSA medium) were binding and regulatory protein, on the inner acrosomal mem- incubated with predetermined saturating doses (6-12 ug/ml) brane (2-4). Sperm MCP has cofactor activity for factor of murine anti-human monoclonal IgG specific for MCP I-mediated cleavage of C3, and one of its apparent functions (mAb H316) (2) and the complement receptors CR1 (mAb is protection of sperm from the lytic consequences of com- YZ-1) (11), CR2 (mAb HB-5) (12), or CR3 (mAb OKM1) (13) plement resulting from interactions with antisperm antibod- ies (5). However, sperm MCP is a tissue-specific isoform Abbreviations: C3, complement component 3; MCP, membrane characterized by differential glycosylation (5) and deletions cofactor protein; CR1, -2, and -3, complement receptor types 1, 2, resulting in a shorter transmembrane region and distinctive and 3, respectively; AR, acrosome reaction; mAb, monoclonal cytoplasmic tail (6); this suggests that sperm MCP may have antibody; FITC, fluorescein isothiocyanate; TRITC, tetramethyl- rhodamine B isothiocyanate; NHS, normal human serum; HI-NHS, heat-inactivated normal human serum; HSA, human serum albumin; The publication costs of this article were defrayed in part by page charge PSA, Pisum sativum agglutinin. payment. This article must therefore be hereby marked "advertisement" tTo whom reprint requests should be addressed at: 250 Longwood in accordance with 18 U.S.C. §1734 solely to indicate this fact. Avenue, Room 204, Boston, MA 02115. 10051 Downloaded by guest on October 2, 2021 10052 Developmental Biology: Anderson et al. Proc. Natl. Acad. Sci. USA 90 (1993) for 60 min at 4°C. mAbs were purified as described (11). nique and capacitated in SWM for 1 hr at 37°C, were Control isotype-matched mAbs included MOPC-21 (IgGl; incubated with dimeric C3b (concentrations as above) and Sigma), HLe-1 (IgGl; Becton Dickinson) and HLA-DR antibodies or with SWM medium alone for 1 hr at 37°C. (IgG2a; Becton Dickinson). Sperm were washed in F-10/ Identically treated oocytes and sperm were then combined in HSA by centrifugation at 4°C for 10 min at 400 x g and organ culture dishes (Falcon) and incubated at 37°C in 5% resuspended to 1 x 106 per ml in F-10/HSA medium. Oocytes CO2 for 3 hr. Oocytes were then washed twice in SWM were washed by transfer through three 0.1-ml drops of medium and examined under phase-contrast microscopy for F-10/HSA. Gametes were then stained with affinity-purified evidence of sperm penetration. fluorescein isothiocyanate (FITC)-coupled F(ab')2 goat anti- Acrosin C3 Cleavage Studies. An acrosin-enriched extract mouse F(ab')2 at 5 ug/ml (Jackson ImmunoResearch). To containing =100 milli-international units of acrosin per ml determine whether complement was activated by gametes was prepared from 108 fresh human sperm by the acid- and whether C3 products were deposited on their surface, extraction method (17). To study the dose dependence of sperm or ova were incubated for 30 min at 37°C with normal acrosin-mediated C3 cleavage, replicate 0.05-ml samples of human serum (NHS), NHS that had been heat-inactivated 125I-labeled C3 (0.5 mg/ml) were incubated at 37°C for 30 min (HI-NHS) at 56°C for 30 min, or NHS treated with 10 mM with an equal volume of Hanks' balanced salt solution EDTA (Sigma). Washed gametes were then incubated in 50% without cations (HBSS), with an equal volume of trypsin (1 normal goat serum for 10 min (blocking step) and assessed for mg/ml in HBSS; Worthington), with 2-50 p1 of acrosin bound C3 products by direct fluorescent staining at 4°C with extract diluted to 50 ul in HBSS, or with 50 Al of hyaluroni- FITC-coupled F(ab')2 goat anti-human C3 (25 Ag/ml; Cap- dase (2 mg/ml in HBSS). The time dependence of acrosin- pel). To detect binding of dimeric C3b, gametes were incu- mediated cleavage ofC3 was analyzed by incubating replicate bated with a 1 uM solution of dimeric C3b in F-10/HSA samples of 25 ,g of 125I-labeled C3 (0.5 mg/ml) at 37°C for up medium for 60 min at 4°C and visualized by immunofluores- to 30 min with either 0.05 ml of acrosin extract or with 10 pg cent staining by using affinity-purified FITC-coupled F(ab')2 oftrypsin (1 mg/ml) in 50-,l volumes. Samples were resolved goat anti-human C3. FITC-coupled F(ab')2 goat anti-mouse on a SDS/5-15% polyacrylamide gel and visualized by IgG was also run for each assay condition to serve as a autoradiography. negative control. Gametes were examined for fluorescence by using a Zeiss epifluorescence microscope. Photomicro- graphs were taken with a Nikon camera on Kodak Tri-X or RESULTS Ektar 400 ASA film.
Recommended publications
  • C3b Catalog Number: A114 Sizes Available
    Name: C3b Catalog Number: A114 Sizes Available: 250 µg/vial Concentration: 1.0 mg/mL (see Certificate of Analysis for actual concentration) Form: Liquid Purity: >90% by SDS-PAGE Buffer: 10 mM sodium phosphate, 145 mM NaCl, pH 7.3 Extinction Coeff. A280 nm = 1.03 at 1.0 mg/mL Molecular Weight: 176,000 Da (2 chains) Preservative: None, 0.22 µm filtered Storage: -70oC or below. Avoid freeze/thaw. Source: Normal human serum (shown by certified tests to be negative for HBsAg and for antibodies to HCV, HIV-1 and HIV-II). Precautions: Use normal precautions for handling human blood products. Origin: Manufactured in the USA. General Description C3b is derived from native C3 upon cleavage and release of C3a. It is prepared by cleavage with the alternative pathway C3 convertase. This is important because only a single bond in C3 is cleaved by the native convertase, while cleavage by other proteases, such as trypsin, results in multiple cleavages at many other sites in the protein. Native human C3b is a glycosylated (~2.8%) polypeptide containing two disulfide-linked chains. C3b is central to the function of all three pathways of complement (Law, S.K.A. and Reid, K.B.M. (1995)). Initiation of each pathway generates proteolytic enzyme complexes (C3 convertases) which are bound to the target surface. These enzymes cleave a peptide bond in C3 releasing the anaphylatoxin C3a and activating C3b. For a brief time (~60 µs) this nascent C3b is capable of reacting with and covalently coupling to hydroxyl groups on the target surface.
    [Show full text]
  • PRSS1 Gene Serine Protease 1
    PRSS1 gene serine protease 1 Normal Function The PRSS1 gene provides instructions for making an enzyme called cationic trypsinogen. This enzyme is a serine peptidase, which is a type of enzyme that cuts ( cleaves) other proteins into smaller pieces. Cationic trypsinogen is produced in the pancreas and helps with the digestion of food. Cationic trypsinogen is secreted by the pancreas and transported to the small intestine, where it is cleaved to form trypsinogen. When the enzyme is needed, trypsinogen is cleaved again into its working (active) form called trypsin. Trypsin aids in digestion by cutting protein chains at the protein building blocks (amino acids) arginine or lysine, which breaks down the protein. Trypsin also turns on (activates) other digestive enzymes that are produced in the pancreas to further facilitate digestion. A particular region of trypsin is attached (bound) to a calcium molecule. As long as trypsin is bound to calcium, the enzyme is protected from being broken down. When digestion is complete and trypsin is no longer needed, the calcium molecule is removed from the enzyme, which allows trypsin to be broken down. Health Conditions Related to Genetic Changes Hereditary pancreatitis More than 40 mutations in the PRSS1 gene have been found to cause hereditary pancreatitis, a condition characterized by recurrent episodes of inflammation of the pancreas (pancreatitis), which can lead to a loss of pancreatic function. Most of these mutations change single protein building blocks (amino acids) in cationic trypsinogen. Some PRSS1 gene mutations result in the production of a cationic trypsinogen enzyme that is prematurely converted to trypsin while it is still in the pancreas.
    [Show full text]
  • Complement Recognition Pathways in Renal Transplantation
    BRIEF REVIEW www.jasn.org Complement Recognition Pathways in Renal Transplantation Christopher L. Nauser, Conrad A. Farrar, and Steven H. Sacks Medical Research Council Centre for Transplantation, Division of Transplantation Immunology and Mucosal Biology, King’s College London, National Health Service Guy’s and St. Thomas’ Trust, London, United Kingdom ABSTRACT The complement system, consisting of soluble and cell membrane–bound compo- weigh its effect on organ injury and nents of the innate immune system, has defined roles in the pathophysiology of renal rejection with dampening the antimi- allograft rejection. Notably, the unavoidable ischemia-reperfusion injury inherent to crobial functions of the complement sys- transplantation is mediated through the terminal complement activation products tem, such as opsonisation, cell lysis, and C5a and C5b-9. Furthermore, biologically active fragments C3a and C5a, produced recruitment of neutrophils and other in- during complement activation, can modulate both antigen presentation and T cell flammatory cells.7 It is our belief that priming, ultimately leading to allograft rejection. Earlier work identified renal tubule therapeutic strategies can be designed cell synthesis of C3, rather than hepatic synthesis of C3, as the primary source of C3 to specificallytargetthekeyinitiators driving these effects. Recent efforts have focused on identifying the local triggers of of complement activation at the relevant complement activation. Collectin-11, a soluble C-type lectin expressed in renal tis- location, such as complement-binding sue, has been implicated as an important trigger of complement activation in renal anti-HLA antibodies in the vascular tissue. In particular, collectin-11 has been shown to engage L-fucose at sites of compartment or the initiator(s) of local ischemic stress, activating the lectin complement pathway and directing the innate complement activation in the extravas- immune response to the distressed renal tubule.
    [Show full text]
  • Complement Component 3 (C3) Concentrations in Cancer Patients: a Systematic Review and Meta-Analysis
    Complement Component 3 (C3) Concentrations in Cancer Patients: A Systematic Review and Meta-Analysis Zipeng Yang South China Agricultural University Zi-Guo Yuan ( [email protected] ) Anqun Yang Dapeng New District Nan'ao Peolple's Hospital of Shenzhen, Guangdong Province, China Xiu-Xiang Zhang South China Agricultural University College of Agriculture Xiaohu Wang Guangdong Academy of Agricultural Sciences, Guangzhou, Guangdong Province Miao Yu Dongfeng Xiyuan District, Stomatological Hospital Aliated to Guangzhou Medical University, Guangzhou Yasser S.Mahmmod Zagazig University Jorge A Hernandez University of Florida Zhaowen Ren South China Agricultural University Xirui Zhang South China Agricultural University Wei Cong Shandong University Research article Keywords: Complement Component 3, Cancer Patients, Meta-Analysis Posted Date: March 26th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-18256/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/17 Abstract Background The aim of this study was to investigate the association between the serum complement component 3 “C3” level and the patients with different types of cancer. Our study nding would ultimately provide reliable scientic conclusions to guide clinical practice. Methods PubMed, Embase, The Chorane Library and Google Scholar were systematically searched to identify all studies on serum C3 concentrations in cancer patients published as of September 2019. Additionally, we conducted a clinical study on serum C3 in lung cancer patients and healthy people. The levels of serum complement C3 in 84 lung cancer patients and 30 healthy people were examined by ELISA. We used standardized mean differences (SMD) to report the pooled estimation, and I² statistics were calculated to examine the heterogeneity.
    [Show full text]
  • Activation Regulates Alternative Pathway Complement Necrotic
    Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation This information is current as of September 27, 2021. Wei Xu, Stefan P. Berger, Leendert A. Trouw, Hetty C. de Boer, Nicole Schlagwein, Chantal Mutsaers, Mohamed R. Daha and Cees van Kooten J Immunol 2008; 180:7613-7621; ; doi: 10.4049/jimmunol.180.11.7613 Downloaded from http://www.jimmunol.org/content/180/11/7613 References This article cites 56 articles, 27 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/11/7613.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation1,2 Wei Xu,* Stefan P. Berger,* Leendert A.
    [Show full text]
  • An Anticomplement Agent That Homes to the Damaged Brain and Promotes Recovery After Traumatic Brain Injury in Mice
    An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice Marieta M. Rusevaa,1,2, Valeria Ramagliab,1, B. Paul Morgana, and Claire L. Harrisa,3 aInstitute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, United Kingdom; and bDepartment of Genome Analysis, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands Edited by Douglas T. Fearon, Cornell University, Cambridge, United Kingdom, and approved September 29, 2015 (received for review July 15, 2015) Activation of complement is a key determinant of neuropathology to rapidly and specifically inhibit MAC at sites of complement and disability after traumatic brain injury (TBI), and inhibition is activation, and test its therapeutic potential in experimental TBI. neuroprotective. However, systemic complement is essential to The construct, termed CD59-2a-CRIg, comprises CD59a linked fight infections, a critical complication of TBI. We describe a to CRIg via the murine IgG2a hinge. CD59a prevents assembly targeted complement inhibitor, comprising complement receptor of MAC in cell membranes (16), whereas CRIg binds C3b/iC3b of the Ig superfamily (CRIg) fused with complement regulator CD59a, deposited at sites of complement activation (17). The IgG2a designed to inhibit membrane attack complex (MAC) assembly at hinge promotes dimerization to increase ligand avidity. CD59- sites of C3b/iC3b deposition. CRIg and CD59a were linked via the 2a-CRIg protected in the TBI model, demonstrating that site- IgG2a hinge, yielding CD59-2a-CRIg dimer with increased iC3b/C3b targeted anti-MAC therapeutics may be effective in prevention binding avidity and MAC inhibitory activity. CD59-2a-CRIg inhibited of secondary neuropathology and improve neurologic recovery MAC formation and prevented complement-mediated lysis in vitro.
    [Show full text]
  • Complement Component 4 Genes Contribute Sex-Specific Vulnerability in Diverse Illnesses
    bioRxiv preprint doi: https://doi.org/10.1101/761718; this version posted September 9, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Complement component 4 genes contribute sex-specific vulnerability in diverse illnesses Nolan Kamitaki1,2, Aswin Sekar1,2, Robert E. Handsaker1,2, Heather de Rivera1,2, Katherine Tooley1,2, David L. Morris3, Kimberly E. Taylor4, Christopher W. Whelan1,2, Philip Tombleson3, Loes M. Olde Loohuis5,6, Schizophrenia Working Group of the Psychiatric Genomics Consortium7, Michael Boehnke8, Robert P. Kimberly9, Kenneth M. Kaufman10, John B. Harley10, Carl D. Langefeld11, Christine E. Seidman1,12,13, Michele T. Pato14, Carlos N. Pato14, Roel A. Ophoff5,6, Robert R. Graham15, Lindsey A. Criswell4, Timothy J. Vyse3, Steven A. McCarroll1,2 1 Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA 2 Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA 3 Department of Medical and Molecular Genetics, King’s College London, London WC2R 2LS, UK 4 Rosalind Russell / Ephraim P Engleman Rheumatology Research Center, Division of Rheumatology, UCSF School of Medicine, San Francisco, California 94143, USA 5 Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California 90095, USA 6 Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, California 90095, USA 7 A full list of collaborators is in Supplementary Information.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • High-Throughput Proteomic Profiling of the Fish Liver Following Bacterial
    Causey et al. BMC Genomics (2018) 19:719 https://doi.org/10.1186/s12864-018-5092-0 RESEARCH ARTICLE Open Access High-throughput proteomic profiling of the fish liver following bacterial infection Dwight R Causey1, Moritz A N Pohl1, David A Stead2, Samuel A M Martin1, Christopher J Secombes1 and Daniel J Macqueen1* Abstract Background: High-throughput proteomics was used to determine the role of the fish liver in defense responses to bacterial infection. This was done using a rainbow trout (Oncorhynchus mykiss) model following infection with Aeromonas salmonicida, the causative agent of furunculosis. The vertebrate liver has multifaceted functions in innate immunity, metabolism, and growth; we hypothesize this tissue serves a dual role in supporting host defense in parallel to metabolic adjustments that promote effectiveimmunefunction.Whilepaststudieshavereported mRNA responses to A. salmonicida in salmonids, the impact of bacterial infection on the liver proteome remains uncharacterized in fish. Results: Rainbow trout were injected with A. salmonicida or PBS (control) and liver extracted 48 h later for analysis on a hybrid quadrupole-Orbitrap mass spectrometer. A label-free method was used for protein abundance profiling, which revealed a strong innate immune response along with evidence to support parallel rewiring of metabolic and growth systems. 3076 proteins were initially identified against all proteins (n = 71,293 RefSeq proteins) annotated in a single high-quality rainbow trout reference genome, of which 2433 were maintained for analysis post-quality filtering. Among the 2433 proteins, 109 showed significant differential abundance following A. salmonicida challenge, including many upregulated complement system and acute phase response proteins, in addition to molecules with putative functions that may support metabolic re-adjustments.
    [Show full text]
  • The Complement System: a Powerful Modulator and Effector of Astrocyte Function in the Healthy and Diseased Central Nervous System
    cells Review The Complement System: A Powerful Modulator and Effector of Astrocyte Function in the Healthy and Diseased Central Nervous System Marcela Pekna 1,3,4,* and Milos Pekny 2,3,4 1 Laboratory of Regenerative Neuroimmunology, Center for Brain Repair, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, 40530 Gothenburg, Sweden 2 Laboratory of Astrocyte Biology and CNS Regeneration, Center for Brain Repair, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, 40530 Gothenburg, Sweden; [email protected] 3 Florey Institute of Neuroscience and Mental Health, Parkville, Melbourne 3010, Australia 4 School of Medicine and Public Health, University of Newcastle, Newcastle 2308, Australia * Correspondence: [email protected]; Tel.: +46-31-786-3581 Abstract: The complement system, an effector arm of the innate immune system that plays a critical role in tissue inflammation, the elimination of pathogens and the clearance of dead cells and cell debris, has emerged as a regulator of many processes in the central nervous system, including neural cell genesis and migration, control of synapse number and function, and modulation of glial cell responses. Complement dysfunction has also been put forward as a major contributor to neurological disease. Astrocytes are neuroectoderm-derived glial cells that maintain water and ionic homeostasis, and control cerebral blood flow and multiple aspects of neuronal functioning. By virtue of their Citation: Pekna, M.; Pekny, M. The Complement System: A Powerful expression of soluble as well as membrane-bound complement proteins and receptors, astrocytes are Modulator and Effector of Astrocyte able to both send and receive complement-related signals.
    [Show full text]
  • Functional Prediction and Comparative Population Analysis of Variants in Genes for Proteases and Innate Immunity Related to SARS
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.093690; this version posted May 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection Kristel Klaassen1¶, Biljana Stankovic1¶, Branka Zukic1, Nikola Kotur1, Vladimir Gasic1, Sonja Pavlovic1, Maja Stojiljkovic1* 1Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia * Corresponding author E-mail: [email protected] (MS) ¶These authors contributed equally to this work. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.05.13.093690; this version posted May 13, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract New coronavirus SARS-CoV-2 is capable to infect humans and cause a novel disease COVID-19. Aiming to understand a host genetic component of COVID-19, we focused on variants in genes encoding proteases and genes involved in innate immunity that could be important for susceptibility and resistance to SARS-CoV-2 infection. Analysis of sequence data of coding regions of FURIN, PLG, PRSS1, TMPRSS11a, MBL2 and OAS1 genes in 143 unrelated individuals from Serbian population identified 22 variants with potential functional effect.
    [Show full text]
  • Page 1 of 76 Diabetes Diabetes Publish Ahead of Print, Published Online September 14, 2020
    Page 1 of 76 Diabetes Peters, Annette; Helmholtz Center Munich German Research Center for Environmental Health, Epidemiology Institute Waldenberger, Melanie; Helmholtz Center Munich German Research Center for Environmental Health, Molecular Epidemiology Diabetes Publish Ahead of Print, published online September 14, 2020 Diabetes Page 2 of 76 Deciphering the Plasma Proteome of Type 2 Diabetes Mohamed A. Elhadad1,2,3 MSc., Christian Jonasson4,5 PhD, Cornelia Huth2,6 PhD, Rory Wilson1,2 MSc, Christian Gieger1,2,6 PhD, Pamela Matias1,2,3 MSc, Harald Grallert1,2,6 PhD, Johannes Graumann7,8 PhD, Valerie Gailus-Durner9 PhD, Wolfgang Rathmann6,10 MD, Christine von Toerne11 PhD, Stefanie M. Hauck11 PhD, Wolfgang Koenig3,12,13 MD, FRCP, FESC, FACC, FAHA, Moritz F. Sinner3,14 MD, MPH, Tudor I Oprea15,16,17 MD, PhD, Karsten Suhre18 PhD, Barbara Thorand2,6 PhD, Kristian Hveem4,5 PhD, Annette Peters2,3,6,19 PhD, Melanie Waldenberger1,2,3 PhD 1. Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 2. Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany 3. German Research Center for Cardiovascular Disease (DZHK), Partner site Munich Heart Alliance, Germany 4. K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU - Norwegian University of Science and Technology, Trondheim, Norway 5. HUNT Research Center, Department of Public Health, NTNU - Norwegian University of Science and Technology, Levanger, Norway 6. German Center for Diabetes Research (DZD), München-Neuherberg, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany 7. Biomolecular Mass Spectrometry, Max Planck Institute for Heart and Lung Research, Ludwigstrasse 43, Bad Nauheim 61231, Germany 8.
    [Show full text]